-
Product Insights
NewAC Immune SA Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our AC Immune SA Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. AC Immune SA (AC Immune) is a clinical-stage biopharmaceutical company that discovers, designs and develops proprietary medicines to prevent, diagnose and treat neurodegenerative diseases associated with protein misfolding. The company develops drugs based on its two proprietary technology platforms: SupraAntigen and Morphomer. Its technology platforms help the company to design, discover and develop antibodies, small molecules and vaccines. AC...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AC-0676 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AC-0676 in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AC-0676 in Follicular Lymphoma Drug Details: AC-0676 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AC-0676 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AC-0676 in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AC-0676 in Mantle Cell Lymphoma Drug Details: AC-0676 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AC-0676 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AC-0676 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AC-0676 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: AC-0676...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AC-0676 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AC-0676 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AC-0676 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AC-0676 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AC-0676 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AC-0676 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AC-0676 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AC-0676 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AC-0676 in Marginal Zone B-cell Lymphoma Drug Details: AC-0676...
-
Product Insights
ACE Group – Ace YXP Mixed-Use Complex – Uttar Pradesh
The ACE Group – Ace YXP Mixed-Use Complex – Uttar Pradesh involves the construction of a mixed-use complex on 16,000m2 of land in Sector 22D, Noida, Uttar Pradesh, India. Equip yourself with the essential tools needed to make informed and profitable decisions with our ACE Group – Ace YXP Mixed-Use Complex – Uttar Pradesh report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the...
-
Product Insights
Chasing Aces Ent – Chasing Aces Golf Entertainment Complex – Louisiana
The Chasing Aces Ent – Chasing Aces Golf Entertainment Complex – Louisiana involves the construction of a golf entertainment complex on 11ha of land in Bossier City, Louisiana, the US. Equip yourself with the essential tools needed to make informed and profitable decisions with our Chasing Aces Ent – Chasing Aces Golf Entertainment Complex – Louisiana report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days...